143 related articles for article (PubMed ID: 15703207)
41. B-cell dysfunction and depletion using mycophenolate mofetil in a pediatric combined liver and kidney graft recipient.
Ganschow R; Lyons M; Kemper MJ; Burdelski M
Pediatr Transplant; 2001 Feb; 5(1):60-3. PubMed ID: 11260491
[TBL] [Abstract][Full Text] [Related]
42. Post-renal transplant surgical complications with newer immunosuppressive drugs: mycophenolate mofetil vs. m-TOR inhibitors.
Srivastava A; Muruganandham K; Vinodh PB; Singh P; Dubey D; Kapoor R; Kumar A; Sharma RK; Prasad N
Int Urol Nephrol; 2010 Jun; 42(2):279-84. PubMed ID: 19557542
[TBL] [Abstract][Full Text] [Related]
43. Tuberculosis in Egyptian kidney transplant recipients: study of clinical course and outcome.
el-Agroudy AE; Refaie AF; Moussa OM; Ghoneim MA
J Nephrol; 2003; 16(3):404-11. PubMed ID: 12832742
[TBL] [Abstract][Full Text] [Related]
44. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study.
Dharnidharka VR; Ho PL; Stablein DM; Harmon WE; Tejani AH
Pediatr Transplant; 2002 Oct; 6(5):396-9. PubMed ID: 12390426
[TBL] [Abstract][Full Text] [Related]
45. [Acute pancreatitis after kidney transplantation].
Asztalos L; Kincses Z; Berczi C; Szabo L; Fedor R; Locsey L; Balzs G
Magy Seb; 2001 Apr; 54(2):91-4. PubMed ID: 11339098
[TBL] [Abstract][Full Text] [Related]
46. [Perioperative agranulocytosis induced by immunosuppressants in a renal graft recipient : a case report].
Matsumoto K; Kobayashi T; Murakami K; Okubo K; Negoro H; Terada N; Sugino Y; Yamasaki T; Matsui Y; Inoue T; Kamba T; Yoshimura K; Ogawa O
Hinyokika Kiyo; 2014 Jun; 60(6):275-8. PubMed ID: 25001642
[TBL] [Abstract][Full Text] [Related]
47. New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression.
Veroux M; Corona D; Giuffrida G; Gagliano M; Sorbello M; Virgilio C; Tallarita T; Zerbo D; Giaquinta A; Fiamingo P; Macarone M; Li Volti G; Caglia P; Veroux P
Transplant Proc; 2008; 40(6):1885-7. PubMed ID: 18675079
[TBL] [Abstract][Full Text] [Related]
48. Cancer Screening of Renal Transplant Patients Undergoing Long-Term Immunosuppressive Therapy.
Demir T; Ozel L; Gökçe AM; Ata P; Kara M; Eriş C; Özdemir E; Titiz MI
Transplant Proc; 2015 Jun; 47(5):1413-7. PubMed ID: 26093731
[TBL] [Abstract][Full Text] [Related]
49. Triple therapy and incidence of de novo cancer in renal transplant recipients.
Kehinde EO; Petermann A; Morgan JD; Butt ZA; Donnelly PK; Veitch PS; Bell PR
Br J Surg; 1994 Jul; 81(7):985-6. PubMed ID: 7922092
[TBL] [Abstract][Full Text] [Related]
50. Elevated tacrolimus trough levels in association with mycophenolate mofetil-induced diarrhea: a case report.
Frühwirth M; Fischer H; Simma B; Ellemunter H
Pediatr Transplant; 2001 Apr; 5(2):132-4. PubMed ID: 11328552
[TBL] [Abstract][Full Text] [Related]
51. Risk Factors for Fractures in Renal Transplantation: A Population-Based Cohort Study.
Tsai HL; Lin TC; Lin NC; Yang HH; Chang JW
Am J Nephrol; 2023; 54(11-12):498-507. PubMed ID: 37783206
[TBL] [Abstract][Full Text] [Related]
52. Effect of mycophenolate mofetil on plasma bioelements in renal transplant recipients.
Kamińska J; Sobiak J; Suliburska JM; Duda G; Głyda M; Krejpcio Z; Chrzanowska M
Biol Trace Elem Res; 2012 Feb; 145(2):136-43. PubMed ID: 21870152
[TBL] [Abstract][Full Text] [Related]
53. Suppression of the humoral immune response by mycophenolate mofetil.
Smith KG; Isbel NM; Catton MG; Leydon JA; Becker GJ; Walker RG
Nephrol Dial Transplant; 1998 Jan; 13(1):160-4. PubMed ID: 9481733
[TBL] [Abstract][Full Text] [Related]
54. [Cancer and immunosuppression: pro- and antitumoral effects of immunosuppressive drugs].
Thaunat O; Morelon E
Nephrol Ther; 2005 Mar; 1(1):23-30. PubMed ID: 16895664
[TBL] [Abstract][Full Text] [Related]
55. The pattern of mucocutaneous infections and infestations in renal transplant recipients.
Sandhu K; Gupta S; Kumar B; Dhandha R; Udigiri NK; Minz M
J Dermatol; 2003 Aug; 30(8):590-5. PubMed ID: 12928527
[TBL] [Abstract][Full Text] [Related]
56. Congenital Infections in Neonates of Women With Liver or Kidney Transplants.
Kociszewska-Najman B; Pietrzak B; Czaplinska N; Cyganek A; Jabiry-Zieniewicz Z; Schreiber-Zamora J; Drozdowska-Szymczak A; Bobrowska K; Wielgos M
Transplant Proc; 2016 Jun; 48(5):1556-60. PubMed ID: 27496446
[TBL] [Abstract][Full Text] [Related]
57. A review of heart transplant immunosuppressants and nonmelanoma skin cancer.
Eckembrecher DG; Eckembrecher FJ; Camacho I; Shah H; Dave Y; Patel S; Nouri K
Arch Dermatol Res; 2023 Nov; 315(9):2491-2503. PubMed ID: 37256379
[TBL] [Abstract][Full Text] [Related]
58. Predictable and Unusual Adverse Effects of Immunosuppression in Pediatric Liver Transplant Patients.
Öztürk H; Ekşi Bozbulut N; Sarı S; Eğritaş Gürkan Ö; Sözen H; Sapmaz A; Dalgıç A; Dalgıç B
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):230-233. PubMed ID: 30777562
[TBL] [Abstract][Full Text] [Related]
59. Azathioprine, UV light, and skin cancer in organ transplant patients--do we have an answer?
Ulrich C; Stockfleth E
Nephrol Dial Transplant; 2007 Apr; 22(4):1027-9. PubMed ID: 17234668
[No Abstract] [Full Text] [Related]
60. Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone?
Jensen P; Hansen S; Møller B; Leivestad T; Pfeffer P; Fauchald P
Transplant Proc; 1999; 31(1-2):1120. PubMed ID: 10083500
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
